Ainos Licenses VELDONA Platform to BioPhoenix for $600K Upfront, Up to $10M Framework
AIMD is trading near its 52-week low of $1.25 (11% above the low).
Summary
Ainos granted BioPhoenix an exclusive worldwide license to its VELDONA platform for Sjögren's Disease and Thrombocytopenia, receiving a $600,000 upfront fee, 25% of net sublicensing revenue, and a potential $10 million framework if all additional indications are licensed.
Key Events · M&A and Partnerships · AIMD
-
Global Exclusive VELDONA License Signed
Ainos granted BioPhoenix Co., Ltd. an exclusive, worldwide, irrevocable, transferable, sublicensable license to its VELDONA low-dose oral interferon alpha platform for Sjögren's Disease and Thrombocytopenia, including manufacturing rights.
-
$600K Upfront Fee, $10M Potential Framework
BioPhoenix will pay a $600,000 upfront license fee due within 15 business days after technology transfer completion, plus a one-time first sublicense fee and 25% of net sublicensing revenue. If all 15 additional indications are licensed, total license fees could reach approximately $10.0 million.
-
Partner Funds Clinical and Regulatory Work
BioPhoenix assumes funding and execution of assigned clinical and regulatory activities for the two licensed indications, reducing Ainos' need to independently finance development — a critical relief given Ainos' $1.4 million cash balance and going concern warning.
-
10-Year Non-Compete and ROFR Granted
Ainos cannot compete with the Licensed Indications worldwide during the term and for 10 years after termination. BioPhoenix also received a right of first refusal and call option on additional VELDONA indications that have progressed to Phase 2 clinical trials.
Analysis · AIMD · Technology
Ainos has monetized its VELDONA low-dose oral interferon alpha platform through a global exclusive license to Taiwan-based BioPhoenix for Sjögren's Disease and Thrombocytopenia. The deal brings a $600,000 upfront fee — nearly half of the $1.4 million in cash Ainos reported in August — plus 25% of net sublicensing revenue and a potential $10 million total framework if all 15 additional indications are licensed. Critically, BioPhoenix funds and executes all assigned clinical and regulatory work, which removes a major cash drain from Ainos at a time when the company is fighting a going concern warning. The trade-off is significant: Ainos grants an irrevocable, worldwide exclusive license and agrees not to compete in those indications for 10 years after the agreement ends. For a company with near-zero revenue and persistent going concern risk, this is a meaningful step toward survival and strategic focus on its AI Nose / Chemical Intelligence business.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AIMD was trading at $1.39 on NASDAQ in the Technology sector, with a market capitalization of approximately $9.9M. The 52-week trading range was $1.25 to $4.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.